) is set to report its fiscal Q2 ’24 financial results before the opening bell tomorrow morning, Thursday, March 28th, 2024. Analyst consensus is expecting $38.9 billion in revenue, $672 million in operating income, and $0.82 in EPS, resulting in +3%, – 45%, and -29% yoy growth for the three metrics.
The US Healthcare segment, which was Roz Brewer’s baby was expected to show significant year-on-year profit improvement in fiscal ’24, per the conference call notes. The most troubling valuation metric WBA’s “price-to-revenue” or price-to-sales metric at 0.12x. That’s lower than when Sears Holdings was taken out, or when Michael Dell took Dell (NYSE:
One-time asset liquidations and asset divestitures at WBA are a plus for now, but the business needs to stabilize margins and eventually improve operating income on a reliable basis. A few clients are long the stock between $21 – $23, but it’s not a big position. To own more stock, I would need to see the EPS estimates stabilize and even better, move higher. That would tell me earnings are more in line with revenue.